A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Third Parties

NCT00980317 | Unknown DMC

• 1 other identifier: TW062090715KT
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 2

Brief Summary

Approximately 30,000 new patients are introduced into dialysis and about 20,000 of them die every year in Japan. At present, about 300,000 patients are on dialysis and more than 10,000 patients are registered to the Japan Organ Transplant Network (JOTN) with the hope for a renal transplantation. If the renal function is restored by transplantation, the quality of life (QOL) improves and more than 90% are reportedly come back to their normal life activities and get relieved from the burden of dialysis. Furthermore, it can reduce the dialysis related medical cost by as much as 50%. However, only about 1,000 renal transplantation cases are annually carried out in Japan. Among them, 80-85% are living renal transplantations offered by family members or relatives, and the rest are from deceased donors. Due to the fact that the number of deceased donors are scarce and renal transplantations between non-relatives (third parties) are currently not allowed in Japan, the approximate waiting time to receive a renal transplantation is 16 years. For that reason, many patients travel abroad to receive a renal transplantation. There are reports that total nephrectomies are performed as a treatment for small size (4 cm or less) renal tumors in many cases and that many of these nephrectomized kidneys can be successfully transplanted after surgical restoration with satisfactory results. However, due to the lack of necessary evidence it is currently not allowed in Japan. Therefore, the investigators planned the present clinical study to evaluate the curative efficacy (renal function, QOL) and safety (side effects, complications or occurence of renal cancer) of living renal transplantations between third parties (non-relatives) with restored donor kidneys after the surgical removal of a small size (4 cm or less) renal tumor, in order to acquire necessary clinical data for potential enrichment of the renal donor pool in Japan as well as to develop useful medical care for our patients who are on dialysis for many years due to the renal failure.

Conditions

Kidney Neoplasms; Renal Insufficiency; Renal Replacement Therapy

Keywords

Renal tumor; Restored kidney; Renal transplantation; Third party

Outcome Measures

Primary Outcomes (1)

• Evaluation of curative efficacy (renal function and QOL) and safety (side effects, complications or occurence of renal cancer) after renal transplantation with restored donor kidneys to third party recipients

  12 Months

Interventions

Restored Kidney Transplant Between Third Parties PROCEDURE

Tumor part of the donor kidney is surgically removed and the kidney is restored and transplanted to a third party recipient

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Recipient:
• Patients who are on dialysis and are willing to receive a restored kidney from a third party
• Patients who are eligible for general anesthesia
• Patients who have given written informed consent to participate in the study
• Donor:
• Patients who have small tumor (size: \<4 cm) in the kidney and have chosen total nephrectomy among all the available treatment options and have permitted to transplant the nephrectomized kidney to a third party upon its surgical restoration
• Patients who are eligible for general anesthesia
• Patients who have given written informed consent to participate in the study

You may not qualify if:

• Recipient:
• Patients who have infectious disease, hemorrhagic ulcer, or malignant cancer
• Patients who have serious vascular lesions (eg. arteriosclerosis, thromboembolic disease) and are currently on treatment
• Patients who were disapproved by the Institutional Ethics Committee
• Donor:
• Patients who have tested positive for serious infectious disease (eg. HIV, HBV, or HCV)
• Patients who were diagnosed with malignant lymphoma or sarcoma
• Patients who were on chemotherapy or radiation therapy for renal cancer prior to the nephrectomy
• Patients who were disapproved by the Institutional Ethics Committee

Sponsors & Collaborators

• Tokushukai Medical Group: lead

Study Sites (2)

Uwajima Tokushukai Hospital

Uwajima, Ehime, 798-0003, Japan

RECRUITING

Tokyo-West Tokushukai Hospital Transplant Office

Akishima, Tokyo, 196-0003, Japan

RECRUITING

MeSH Terms

Conditions

Kidney Neoplasms; Renal Insufficiency; Carcinoma, Renal Cell

Condition Hierarchy (Ancestors)

Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Kidney Diseases; Urologic Diseases; Male Urogenital Diseases; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type

Study Officials

• Yoshihide Ogawa, MD, PhD

  Tokyo-West Tokushukai Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yoshihide Ogawa, MD, PhD

CONTACT

+81-42-500-4433; transplant-office@tokushukai.jp

Yoshihide Ogawa, MD, PhD

CONTACT

+81-42-500-4433; yoshihide.ogawa@tokushukai.jp

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: September 17, 2009
• First Posted: September 21, 2009
• Study Start: July 1, 2009
• Primary Completion: June 1, 2014
• Study Completion: June 1, 2014
• Last Updated: October 14, 2009

Record last verified: 2009-10

Locations

JP (2)